Handa Pharmaceuticals (Taiwan) Today
| 6620 Stock | TWD 58.20 0.10 0.17% |
Performance0 of 100
| Odds Of DistressLess than 37
|
Handa Pharmaceuticals is selling for under 58.20 as of the 25th of November 2024; that is 0.17% down since the beginning of the trading day. The stock's lowest day price was 56.8. Handa Pharmaceuticals has about a 37 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Handa Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of December 2022 and ending today, the 25th of November 2024. Click here to learn more.
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company also develops modified release dosage forms, such as orally disintegrating tablets, modified release orally disintegrating tablets, modified release suspension systems, and ophthalmic modified release systems. The company has 115.57 M outstanding shares. More on Handa Pharmaceuticals
Moving together with Handa Stock
Moving against Handa Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Handa Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Handa Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Handa Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Handa Pharmaceuticals (6620) is traded on Taiwan OTC Exchange in Taiwan and employs 9 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Handa Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Handa Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Handa Pharmaceuticals operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 115.57 M outstanding shares.
Handa Pharmaceuticals has accumulated about 315.09 M in cash with (308.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.72.
Check Handa Pharmaceuticals Probability Of Bankruptcy
Handa Pharmaceuticals Risk Profiles
Although Handa Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Handa Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.52 | |||
| Standard Deviation | 2.34 | |||
| Variance | 5.48 | |||
| Risk Adjusted Performance | (0.17) |
Handa Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Handa Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Handa Pharmaceuticals Corporate Management
Elected by the shareholders, the Handa Pharmaceuticals' board of directors comprises two types of representatives: Handa Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Handa. The board's role is to monitor Handa Pharmaceuticals' management team and ensure that shareholders' interests are well served. Handa Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Handa Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weili Lin | Independent Director | Profile | |
| Meifang Zhang | Director | Profile | |
| Guiqing Wang | Independent Director | Profile | |
| Fangyu Liu | Chairman of the Board | Profile | |
| Xinyu Chen | Deputy General Manager-Finance | Profile | |
| Junliang Chen | General Manager, Director | Profile |
Additional Tools for Handa Stock Analysis
When running Handa Pharmaceuticals' price analysis, check to measure Handa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Handa Pharmaceuticals is operating at the current time. Most of Handa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Handa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Handa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Handa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.